News

Results showed an 82% reduction in the rate of relapses (annualized relapse rate) over a period of up to two years with oral Gilenya compared to treatment with interferon

The company did not reveal the exact reason behind the withdrawal of the Marketing Authorisation Application (MAA) of the Keytruda combination. However, the company's move is due to an

“About 80 percent of women with ovarian cancer are diagnosed in the advanced stages when the disease is difficult to treat and options are limited,” said Sandra Horning,

"We are excited to work with TESARO, an oncology-focused biopharmaceutical company, to evaluate the possible synergistic effects of combining ZEJULA with oregovomab in this important clinical setting," stated

Synthon is the partner of the US-based Mylan for the development and supply of its Glatiramer Acetate Injection 40mg/mL product across Europe. The 3-times-a-week injection is the substitutable

The new investment at the Limerick Industrial Operations and Product Supply (IOPS) campus will create an additional 300 new jobs. Regeneron has taken its total investment for the

"This study demonstrates the feasibility of using genome-wide molecular tests to guide treatment in recurrent glioblastoma," according to a scientific paper published today in Clinical Cancer Research, a journal

Of these variants, reported today in the journals Nature and Nature Genetics, 65 are common variants that predispose to breast cancer and a further seven predispose specifically to

Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination